The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep
Often characterized by involuntary motor or vocal tics, Tourette syndrome typically appears in childhood and affects up to ...
After finishing last season with Patrick Mahomes, DeAndre Hopkins gets to play with Lamar Jackson
DeAndre Hopkins moved from one two-time MVP quarterback to another. After reaching the Super Bowl last season with Patrick ...
New York Magazine6d
Can Anything Stop Bird Flu?
Bird flu. With that diagnosis in mind, one of Russo’s colleagues tried to get some bovine samples tested for H5N1, but the ...
Our culture is addicted to pleasure and starving for meaning — Richard Kyte
Digital distractions, endless entertainment and convenience culture shape behavior, making true engagement with creativity, ...
Karolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial
PharmNovo conducted a regulatory pre-IND Type B meeting with the FDA in January 2025. Such meetings are typically held before submitting an Investigational New Drug (IND) application, which is ...
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
OKYO Pharma Limited (NASDAQ:OKYO ), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA ...
Monthly Prescribing Reference6d
Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM
HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared ...
eLife5d
Brief disruption of activity in a subset of dopaminergic neurons during consolidation impairs long-term memory by fragmenting sleep
Learn more about eLife assessments Sleep disturbances are associated with poor long-term memory (LTM) formation, yet the underlying cell types and neural circuits involved have not been fully decoded.
pharmaphorum3d
Small study finds GLP-1 drug can curb excess alcohol use
Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...
thecardiologyadvisor.com6d
GLP-1 Receptor Agonists May Have Broader Range of Benefits, Risks
Kidney stones are among the possible risks of GLP-1 use that were not previously known. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have a wider range of benefits and risks than what the ...